Literature DB >> 113460

Inhibition of the in vitro growth of Plasmodium falciparum. I. The effects of immune serum and purified immunoglobulin from owl monkeys.

R T Reese, M R Motyl.   

Abstract

Sera from Aotus sp. monkeys (karyotypes II, III, and IV) which were immune to Plasmodium falciparum have been used to inhibit the in vitro growth of this human malaria parasite. Culture conditions used for the assays allowed 50- to 100-fold increases in the number of A+ erythrocytes infected in a 96-hr period in control cultures. Although normal monkey serum did not support growth as well as normal human serum, mixtures of normal monkey and human serum were found that did. Compared to such controls, as little as 3.5% immune monkey serum was found to cause approximately 56% inhibition in 4 days (2 replicative cycles). Purified globulin from immune monkeys inhibited 40% at 2 mg/ml and 75% at 7 mg/ml after a single replicative cycle. These data suggest that serum antibody is likely to play a major role in providing Aotus monkeys with protective immunity to P. falciparum.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 113460

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  14 in total

1.  Antibodies to a conserved-motif peptide sequence of the Plasmodium falciparum thrombospondin-related anonymous protein and circumsporozoite protein recognize a 78-kilodalton protein in the asexual blood stages of the parasite and inhibit merozoite invasion in vitro.

Authors:  P Sharma; A Bharadwaj; V K Bhasin; V N Sailaja; V S Chauhan
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

2.  Antibody-independent inhibition of Plasmodium falciparum in vitro cultures.

Authors:  B L Perlaza; M A Herrera; A Villegas; G Carrasquilla; S Herrera
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

3.  Characterization of protective epitopes in a highly conserved Plasmodium falciparum antigenic protein containing repeats of acidic and basic residues.

Authors:  P Sharma; A Kumar; B Singh; A Bharadwaj; V N Sailaja; T Adak; A Kushwaha; P Malhotra; V S Chauhan
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  A role for rheumatoid factor enhancement of Plasmodium falciparum schizont inhibition in vitro.

Authors:  T J Green; B J Packer
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

5.  Serum inhibition of merozoite dispersal from Plasmodium falciparum schizonts: indicator of immune status.

Authors:  T J Green; M Morhardt; R G Brackett; R L Jacobs
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

6.  Analysis of inhibitory epitopes in the Plasmodium falciparum rhoptry protein RAP-1 including identification of a second inhibitory epitope.

Authors:  R F Howard; K C Jacobson; E Rickel; J Thurman
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

7.  Monkey-derived monoclonal antibodies against Plasmodium falciparum.

Authors:  H A Stanley; R T Reese
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

Review 8.  Malaria: immunity and prospects for vaccination.

Authors:  M Hommel
Journal:  West J Med       Date:  1981-10

9.  Expression of Plasmodium falciparum surface antigens in Escherichia coli.

Authors:  F Ardeshir; J E Flint; R T Reese
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

10.  Association between human serum-induced crisis forms in cultured Plasmodium falciparum and clinical immunity to malaria in Sudan.

Authors:  J B Jensen; M T Boland; J S Allan; J M Carlin; J A Vande Waa; A A Divo; M A Akood
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.